Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) Short Interest Update

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 87,272 shares, a drop of 39.6% from the August 15th total of 144,506 shares. Based on an average daily volume of 14,783 shares, the days-to-cover ratio is presently 5.9 days. Currently, 0.7% of the shares of the stock are sold short.

Nasus Pharma Trading Down 3.4%

Shares of NSRX traded down $0.12 during midday trading on Friday, hitting $3.41. 9,291 shares of the company traded hands, compared to its average volume of 85,239. The stock has a 50-day moving average of $3.47 and a 200-day moving average of $3.23. Nasus Pharma has a one year low of $1.98 and a one year high of $9.50.

Nasus Pharma (NYSEAMERICAN:NSRX) last released its quarterly earnings data on Monday, August 17th. The company reported ($0.27) EPS for the quarter. On average, equities analysts forecast that Nasus Pharma will post -0.93 EPS for the current fiscal year.

Nasus Pharma Company Profile

Nasus Pharma Ltd. is an Israel-based specialty pharmaceutical company focused on developing intranasal treatments for acute medical conditions. The company’s platform is designed to deliver drug powders through the nose, with the goal of offering convenient, needle-free alternatives to certain injectable therapies.

Nasus Pharma’s development activities center on intranasal pharmaceutical products intended for rapid administration in emergency and urgent-care settings. Its pipeline has included candidates targeting conditions in which fast drug delivery may be important, although the availability and development status of individual products may change as clinical and regulatory work progresses.

The company conducts its research and development activities in Israel and is seeking to advance its intranasal drug-delivery technology for potential use in international markets.